• -
  • English
  • Japanese
  • Korean
市場調查報告書
商品編碼
986582

抗凝固劑的全球市場預測(2020年∼2026年)

Anticoagulants Market 2020-2026
出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內，全球抗凝劑市場規模將以顯著的複合年增長率增長。心臟病的患病率增加和新抗凝劑的推出是市場上的主要趨勢。由於全球久坐的生活方式和肥胖人口，心臟病的患病率上升。根據世界衛生組織（WHO）的數據，2016年有超過19億的18歲以上成年人超重。在這些成年人中，超過6.5億肥胖。肥胖與罹患心血管疾病（CVD），尤其是冠心病（CHD）和心力衰竭（HF）的風險增加有關。這增加了對急性冠脈綜合徵的抗凝治療的需求。它對治療和預防肺栓塞和靜脈血栓形成有效。維生素K拮抗劑是長期治療患有冠心病的患者（主要是在急性冠脈綜合徵（ACS）之後）的一種公認的口服抗凝劑。

本報告提供全球抗凝固劑市場相關調查分析，提供市場概要，市場決策要素，市場區隔，競爭情形，各地區分析，主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 規則和規則

第3章 競爭情形

  • 企業佔有率分析
  • 主要策略分析
  • 主要企業分析
    • Johnson&Johnson Services, Inc.Bristol Myers Squibb, Co.Pfizer, Inc.
    • 第一三共
    • Boehringer Ingelheim GmbH

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 各類型市場
    • 新的口服抗凝固劑(NOAC)
    • 維他命K拮抗劑
    • 肝素和低分子量肝素(LMWH)
  • 各應用領域市場
    • 肺動脈栓塞
    • 心房纖維顫動/心肌梗塞(心臟病發作)
    • 深部靜脈血栓症(DVT)
    • 其他

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • AstraZeneca plc
  • Baxter International, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Cipla, Ltd.
  • 第一三共
  • Dr. Reddy's Laboratories, Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Lupin, Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer, Inc.
  • Portola Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries, Ltd.
目錄
Product Code: OMR2023154

Global Anticoagulants Market Size, Share & Trends Analysis Report, By Type (Novel Oral Anticoagulants, Vitamin K Antagonist, and Heparin and Low Molecular Weight Heparin), By Application (Pulmonary Embolism, Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis, and Others) and Forecast, 2020-2026

The global anticoagulants market is estimated to grow at a significant CAGR during the forecast period. The rising prevalence of heart diseases and the increasing launches of new anticoagulants are some key trends reported in the market. An increasing prevalence of heart diseases has been reported globally owing to the sedentary lifestyle habits and obese population across the globe. As per the World Health Organization (WHO), in 2016, over 1.9 billion adults aged 18 years and over were overweight. Among these adults, more than 650 million adults were obese. Obesity is linked with an augmented risk of developing CVD, especially coronary heart disease (CHD) and heart failure (HF). This is resulting in an increasing demand for anticoagulant treatment for acute coronary syndromes. It is effective to treat and prevent pulmonary emboli and venous thrombosis. Vitamin K antagonists are one of the oral anticoagulants demonstrated for long-term therapy of patients suffering from CHD, primarily after an acute coronary syndrome (ACS).

Geographically, Asia-Pacific is estimated to witness significant growth during the forecast period owing to the rising prevalence of CVD and increasing awareness regarding heart diseases in the region. Favorable government initiatives for CVD is supporting to drive public awareness. Since 2010, the Indian Government has been implementing National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) which aims to increase awareness and reinforce infrastructure for screening, early detection, and treatment of these conditions. This is resulting in an increasing demand for anticoagulants that are used to prevent the blood from clotting as rapidly or as potentially as normal.

Some key players in the market include Johnson & Johnson Services, Inc., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH. Some key strategies adopted by the market players include mergers and acquisitions and product launches. For instance, in January 2019, AMAG Pharmaceuticals, Inc. acquired Perosphere Pharmaceuticals Inc., a biopharmaceutical firm. With this acquisition, AMAG adds ciraparantag to its development portfolio. It is in development for application in patients treated with low molecular weight heparin (LMWH) or novel oral anticoagulants (NOACs).

Research Methodology

The market study of the global anticoagulants market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Anticoagulants Market Research and Analysis by Type

2. Global Anticoagulants Market Research and Analysis by Application

The Report Covers:

Comprehensive research methodology of the global anticoagulants market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global anticoagulants market.

Insights about market determinants that are stimulating the global anticoagulants market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Johnson & Johnson Services, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Bristol Myers Squibb, Co.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Pfizer, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Daiichi Sankyo Company, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Boehringer Ingelheim GmbH
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Anticoagulants Market by Type
    • 5.1.1. Novel Oral Anticoagulants (NOACs)
    • 5.1.2. Vitamin K Antagonist
    • 5.1.3. Heparin and Low Molecular Weight Heparin (LMWH)
  • 5.2. Global Anticoagulants Market by Application
    • 5.2.1. Pulmonary Embolism
    • 5.2.2. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • 5.2.3. Deep Vein Thrombosis (DVT)
    • 5.2.4. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AstraZeneca plc
  • 7.3. Baxter International, Inc.
  • 7.4. Bayer AG
  • 7.5. Boehringer Ingelheim GmbH
  • 7.6. Bristol Myers Squibb Co.
  • 7.7. Cipla, Ltd.
  • 7.8. Daiichi Sankyo Company, Ltd.
  • 7.9. Dr. Reddy's Laboratories, Ltd.
  • 7.10. GlaxoSmithKline plc
  • 7.11. Johnson & Johnson Services, Inc.
  • 7.12. Lupin, Ltd.
  • 7.13. Merck & Co., Inc.
  • 7.14. Mylan N.V.
  • 7.15. Novartis International AG
  • 7.16. Pfizer, Inc.
  • 7.17. Portola Pharmaceuticals, Inc.
  • 7.18. Sanofi S.A.
  • 7.19. Sun Pharmaceutical Industries, Ltd.

LIST OF TABLES

  • 1. GLOBAL ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL NOVEL ORAL ANTICOAGULANTS (NOACS)MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL VITAMIN K ANTAGONISTMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 6. GLOBAL ANTICOAGULANTS IN PULMONARY EMBOLISMTREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL ANTICOAGULANTS IN ATRIAL FIBRILLATION/MYOCARDIAL INFARCTION(HEART ATTACK) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL ANTICOAGULANTS IN DEEP VEIN THROMBOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL ANTICOAGULANTS IN OTHER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 14. EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 16. EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLD ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTICOAGULANTS MARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 2. GLOBALANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 3. GLOBAL ANTICOAGULANTS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)